This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paget Disease of Other Bones기타 뼈의 파젯병 (기타 골의 Paget병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M88.8 | Special Copayment Reduction: V213 (rare disease Special Copayment Reduction)
B. SynonymsPaget disease of other bones, osteitis deformans of other bones, Paget's disease of bone (other sites)
C. Adult onsetLikelihood of first onset in adulthood very high (essentially an adult-only disease) — typically begins after age 50 and is the most common form of Paget disease, involving bones other than the skull such as the pelvis, spine, femur, and tibia.
1. HistoryFirst described by Paget in 1877. Patterns of involvement of the spine, pelvis, and femur outside the skull characterized. Bisphosphonates became standard treatment in the 1990s. SQSTM1 gene discovered in 2003.
2. CausesOsteoclast hyperactivation (genetic predisposition such as SQSTM1 + paramyxovirus hypothesis). Involvement of bones other than the skull, such as the spine, pelvis, femur, tibia, and clavicle.
3. GeneticsSQSTM1 (P392L, etc.), RANK/RANKL/OPG pathway genes. Autosomal dominant familial form and sporadic form.
4. General epidemiologyThe most common sites of involvement in Paget disease, in order, are the pelvis (74%), lumbar spine (58%), femur (55%), skull (42%), and tibia (35%). Involvement of other bones outside the skull is typical, and the polyostotic form is common.
5. PathophysiologyOsteoclast hyperactivation → rapid bone resorption → disorganized bone formation (mosaic bone). Thickening of vertebral bodies compresses the spinal cord and nerve roots. Femoral deformity increases fracture risk. Increased vascularity can cause high-output heart failure (with extensive involvement).
6. SymptomsPain at the involved site (dull ache, night pain). Spinal symptoms (low back pain, radiating pain, spinal cord compression). With pelvic, femoral, or tibial involvement, gait abnormalities and bowing deformity. Fracture risk with involvement outside the skull (fragility fractures, stress fractures). Some are asymptomatic.
7. SignsMarked ALP elevation. Warmth and tenderness at the involved site. Femoral bowing deformity (sabre tibia). Hot spots on bone scintigraphy. X-ray: mixed sclerotic-lucent lesions, bone expansion and thickening. Spinal MRI: findings of spinal canal stenosis and compression.
8. ScreeningSuspect Paget disease with unexplained ALP elevation at age 50 or older. Determine the extent of involvement with bone scintigraphy. Confirm characteristic findings with X-ray. Regular ALP testing of first-degree relatives in familial Paget disease.
9. DiagnosisDiagnosed by a combination of imaging (X-ray + bone scintigraphy + MRI) + ALP elevation. Biopsy when Paget sarcoma is suspected. Differential: bone metastases, fibrous dysplasia, osteomyelitis.
10. TreatmentZoledronic acid 5 mg single IV infusion (first choice). Oral bisphosphonates (risedronate, alendronate) as alternatives. Surgery for complications (fracture, spinal cord compression). ALP follow-up.
11. PrognosisGood ALP normalization and symptom control with bisphosphonate treatment. Transformation to Paget sarcoma (<1%) carries the worst prognosis. Nerve damage from spinal complications may be irreversible.
12. PreventionPrimary prevention not possible. Regular follow-up of SQSTM1 families. Fall prevention (fracture prevention). Early bisphosphonate treatment.
13. ReferencesSinger FR et al. Paget's disease of bone … and 9 other references

1. History

Paget disease of other bones has been the most typical and common phenotype of Paget disease since Sir James Paget first described it as "osteitis deformans" in 1877. Even in the patients Paget first described, deformities of various bones outside the skull (especially the spine, pelvis, and femur) were prominent, and subsequent clinical research systematized that Paget disease typically shows multiple bone involvement (polyostotic pattern) or involves a single site outside the skull (monostotic).

With the clinical introduction of X-rays in the early 20th century, the characteristic bone imaging of Paget disease was identified—the "picture frame vertebra" of the vertebral bodies, the "blade of grass" lesions of the femur and tibia, and the mixed sclerotic-lucent findings of the pelvis. These characteristic X-ray findings came to play a decisive role in the clinical diagnosis of Paget disease.

Calcitonin and early bisphosphonates (etidronate) were introduced in the 1970s–80s, and risedronate, alendronate, and pamidronate were approved in turn in the 1990s. In 2005, the results of the HORIZON trial of zoledronic acid confirmed that a single IV infusion had a superior long-term ALP normalization effect compared with risedronate, and it has now become the standard treatment for Paget disease of other bones.

In 2003, the P392L variant of the SQSTM1 (p62) gene was identified as a major cause of familial Paget disease, and subsequently many Paget disease susceptibility genes, including RANK, OPG, TM7SF4 (DC-STAMP), and CSF1R, were discovered through GWAS. Advances in bone scintigraphy, CT, and MRI technology have made assessment of the extent of involvement and early detection of complications in Paget disease of other bones more precise. In East Asia, including Korea, Paget disease of other bones is also markedly rarer than in the West, and few patients are registered for the Special Copayment Reduction (V213).

2. Causes

The cause of Paget disease of other bones is the same as that of Paget disease of the skull. Through complex interactions of genetic predisposition (mainly SQSTM1 variants) and environmental factors (paramyxovirus infection hypothesis), osteoclasts become excessively activated, resulting in abnormally increased bone metabolism. In Paget disease occurring in bones other than the skull, local factors at specific skeletal sites may trigger osteoclast hyperactivation, but the mechanism by which particular sites are selectively involved remains unclear.

The pelvis is the most commonly involved site in Paget disease (about 74% of all Paget patients), followed in reported order by the lumbar spine (58%), femur (55%), skull (42%), tibia (35%), thoracic spine (45%), and humerus (31%). This distribution is from epidemiological data based on whole-body bone scintigraphy. There are reports that single-site (monostotic, mainly 1–2 bones) involvement accounts for about 35% and multiple-site (polyostotic, 3 or more bones) involvement for about 65%. In SQSTM1 variant carriers, multiple-site involvement tends to be more common and to have a more severe course.

As an environmental factor, there is a hypothesis that paramyxovirus (measles, parainfluenza, RSV, etc.) infection persistently infects osteoclast precursors and causes abnormal activation. Some studies have observed structures resembling measles virus nucleocapsid protein within Paget disease osteoclasts, and there are experimental results showing that MV-N protein overactivates normal osteoclasts. However, direct detection of virus in Paget disease has been inconsistent, so this hypothesis is still debated.

3. Genetics

The genetics of Paget disease of other bones share the same genetic background as Paget disease of the skull. Pathogenic variants of the SQSTM1 gene are identified in about 25–40% of familial Paget disease, with P392L the most common variant. In addition, polymorphisms in many genes, including RANK (TNFRSF11A), OPG (TNFRSF11B), TM7SF4, CSF1R, RIN3, and NUP205, contribute to susceptibility to Paget disease.

Genetic differences between multiple-site (polyostotic) and single-site (monostotic) involvement have also been explored in some studies. SQSTM1 variant carriers tend to show multiple-site involvement, earlier onset, and higher ALP levels, so the variant type may be associated with clinical severity. However, predicting specific sites of involvement from genotype is currently impossible.

Variants in the VCP (valosin-containing protein) gene are associated with the rare syndrome "IBMPFD (Inclusion Body Myopathy, Paget disease, Frontotemporal Dementia)," characterized by inclusion body myopathy (IBM), Paget disease, and frontotemporal dementia (FTLD). In this case Paget disease may appear together with myopathy and dementia, so VCP genetic testing is considered when neurological symptoms are present.

4. General epidemiology

Paget disease of other bones is the most common type of involvement in Paget disease overall, and most Paget disease encountered in clinical practice falls into this category. In the West (United Kingdom, Australia, New Zealand, North America), Paget disease occurs in about 2–3% of people aged 55 or older, and in some regions of the United Kingdom in about 7–8% of men aged 70 or older, most of whom have involvement of bones outside the skull.

In the distribution of involved sites in Paget disease, the pelvis (74%), lumbar spine (58%), and femur (55%) are the most common, and all of these fall under "other bones" (M88.8). The most common sites of monostotic Paget disease, involving a single site only, are also the pelvis, femur, and spine. There is a male predominance (male:female about 1.5–2:1), and onset is after age 50.

In East Asia (Korea, Japan, China), Paget disease is very rare, and in Korea few patients with Paget disease of other bones are registered for the rare disease Special Copayment Reduction (V213). A declining trend in the prevalence and severity of Paget disease in the West over recent decades has been reported, which is presumed to reflect changes in environmental factors (reduced viral exposure, dietary changes, etc.). There are studies showing that prevalence also remains low among Asian immigrants, suggesting the importance of genetic factors.

5. Pathophysiology

The pathogenesis of Paget disease of other bones is the same osteoclast hyperactivation–abnormal bone remodeling cycle as in Paget disease of the skull. Specific clinical complications by site of involvement are as follows.

Mechanism of spinal Paget disease: When vertebral bodies (especially lumbar and thoracic) enlarge from Pagetic bone thickening, the spinal canal narrows and spinal cord compression (myelopathy) or nerve root compression (radiculopathy) occurs. A "vascular steal phenomenon" has also been proposed in the Pagetic spine: the abnormally high vascularity of Pagetic bone may divert blood flow from the surrounding spinal cord, causing ischemic myelopathy. This mechanism may partly explain cases of myelopathy that cannot be explained by simple physical compression alone.

Mechanism in the femur and tibia: The femur and tibia are commonly involved in Paget disease, and stress fractures or complete fractures readily occur during the repeated process of bone resorption and formation. In addition, Pagetic bone gradually bows under weight bearing (bowing deformity), causing gait abnormalities and secondary arthritis. The "saber tibia" deformity of the anterior tibia is characteristic.

Mechanism of pelvic Paget disease: Pelvic involvement can lead to Pagetic arthropathy of the hip (hip osteoarthritis). The abnormal structure of Pagetic bone places abnormal loads on the articular cartilage, causing secondary osteoarthritis. High-output heart failure can occur in extensive polyostotic Paget disease of the pelvis, femur, and other bones when the abnormally high vascularity of Pagetic bone overloads the heart.

6. Symptoms

The symptoms of Paget disease of other bones vary with the site and extent of involvement, and many patients are discovered incidentally through ALP elevation or imaging without symptoms.

Bone pain: A dull ache at the involved site is the most common symptom. The pain often persists at night even when lying down, which is important in differentiating it from other musculoskeletal pain. The causes of pain are increased intraosseous pressure due to increased vascularity of Pagetic bone, microfractures due to structural bone abnormalities, and nerve compression.

Spinal symptoms: Low back pain or thoracic back pain is the main symptom of spinal Paget disease. With nerve root compression, radiating lower-limb pain, sensory loss, and muscle weakness appear. In severe cases, lower-limb paralysis and bladder and bowel dysfunction may occur.

Pelvic, femoral, and tibial symptoms: In femoral Paget disease, hip and groin pain and limited motion due to secondary osteoarthritis occur. As bowing deformity of the anterior tibia (saber tibia) progresses, gait abnormalities and secondary knee arthritis appear. When a stress fracture or complete fracture occurs in Pagetic bone, sudden pain and functional impairment result.

Other: High-output heart failure rarely occurs in extensive polyostotic Paget disease. Hyperuricemia and gout are also present in some patients.

7. Signs

The physical and laboratory signs of Paget disease of other bones differ by site of involvement.

Femur and tibia: Bowing deformity of the anterior tibia (saber tibia, sabre tibia) is characteristic and can be seen on inspection. Warmth is palpable over the surface of the affected bone, and marked bone thickening can also be confirmed by palpation. Limited motion and pain at the joints are signs of secondary osteoarthritis.

Spine: Tenderness at the lesion may be found on spinal palpation. On neurological examination, lower-limb weakness, hyperreflexia or hyporeflexia, and sensory abnormalities are identified depending on the degree of spinal cord or nerve root compression.

Laboratory findings: Marked elevation of serum ALP is the most important laboratory finding. Bone-specific ALP is more specific than total ALP. Urinary hydroxyproline or N-telopeptide and C-telopeptide (bone resorption markers) may also be elevated. Calcium, phosphate, and parathyroid hormone are usually normal, and hypercalcemia rarely appears when Paget patients are immobilized.

Imaging findings: On X-ray, expansion and thickening of the involved bone, mixed sclerotic-lucent lesions, and early "blade of grass" lesions (the resorption front in the femur and tibia) are characteristic. In the spine, "picture frame vertebra" and "ivory vertebra" are observed. On bone scintigraphy, hot spots mark active Paget sites. MRI is essential for assessing spinal nerve compression.

8. Screening

There is no general screening test for Paget disease of other bones. In patients aged 50 or older, Paget disease is screened for in the following situations.

Elevated serum ALP: When ALP is elevated with normal liver function, tests to differentiate Paget disease (bone-specific ALP, bone scintigraphy, X-ray) are performed. ALP elevation is the most reliable screening indicator in Paget disease.

Incidental radiologic findings: When characteristic Paget findings are discovered on abdominal CT, spinal X-ray, or MRI taken for other reasons, further evaluation is performed.

Family screening: Monitoring serum ALP every 3–5 years is recommended in first-degree relatives of patients with SQSTM1 variant–positive Paget disease. When ALP elevation is found, the sites of Paget involvement are identified with bone scintigraphy and X-ray.

Symptom-based screening: In people aged 50 or older with localized bone pain persisting even at night, unexplained gait abnormalities or deformity, or progressive neurological symptoms, Paget disease is included in the differential diagnosis and ALP and imaging tests are performed.

9. Diagnosis

The diagnosis of Paget disease of other bones is made by a combination of imaging findings and elevated serum ALP, and biopsy is unnecessary in most cases.

Diagnostic criteria: ① characteristic findings of Paget disease on X-ray or CT (bone expansion and thickening, mixed sclerotic-lucent lesions, cortical thickening, narrowing of the medullary cavity) + ② elevated serum ALP + ③ hot spots on bone scintigraphy. Diagnosis is made when two or more of these three are present.

Differential diagnosis: Exclude bone metastases (identification of the primary cancer, FDG-PET, tumor markers), fibrous dysplasia (onset in childhood–adolescence, GsNα variants), osteomyelitis (fever, leukocytosis, soft tissue involvement on MRI), multiple myeloma (serum protein electrophoresis, bone marrow examination), and Engelmann disease (orphan osteogenesis imperfecta; onset in childhood, TGFB1 variants).

Differentiation of Paget sarcoma: When pain worsens rapidly, ALP rises sharply, or a soft tissue mass develops at an existing Paget lesion, Paget sarcoma is suspected and CT/MRI and biopsy are performed. Because survival is very poor (5-year survival <5%), early recognition is important.

Neurological assessment: When there are symptoms of spinal cord compression in spinal Paget disease, spinal MRI and nerve conduction/electromyography studies are performed to assess the extent of nerve damage. Neurosurgical consultation may be needed to decide on emergency decompression.

10. Treatment

As with Paget disease of the skull, bisphosphonates are the standard treatment for Paget disease of other bones, with surgical intervention added depending on complications.

Zoledronic acid: A single 5 mg IV infusion is currently the most recommended treatment. It achieves long-term (2–6 years) ALP normalization and symptom relief. Hydration and calcium and vitamin D supplementation before infusion are essential. An acute-phase reaction (fever, myalgia, headache) may appear within 1–3 days after infusion and is managed with acetaminophen and fluid intake.

Oral bisphosphonates: Risedronate (30 mg/day for 2 months) and alendronate (40 mg/day for 6 months) are used. They are alternatives in patients with difficult IV access or a high risk of zoledronic acid adverse effects (osteonecrosis of the jaw, renal failure).

Surgical intervention: Nerve decompression (laminectomy, vertebroplasty) is performed for spinal cord compression complicating Pagetic spine, and internal fixation for unstable fractures. Total hip replacement may be needed for Paget-related hip osteoarthritis (preoperative bisphosphonate treatment is recommended to stabilize bone metabolism). Corrective osteotomy for femoral bowing deformity is also rarely performed.

Pain management: NSAIDs or acetaminophen are used for bone pain. When osteoarthritis develops secondarily, physical therapy, assistive devices, and intra-articular steroid injections are helpful.

11. Prognosis

With appropriate bisphosphonate treatment, ALP normalization and symptom control can be achieved in Paget disease of other bones, and the overall prognosis is good. However, if diagnosis is late or complications have already occurred, irreversible damage remains.

ALP normalization and symptom improvement: After zoledronic acid treatment, ALP often normalizes within 2–3 months and bone pain improves markedly. After ALP normalization, remission is maintained for 2–6 years or more without further treatment until relapse.

Neurological complications: When lower-limb paralysis has already occurred due to spinal cord compression, complete recovery is difficult. Early bisphosphonate treatment and, if needed, nerve decompression are important for preserving neurological function.

Fracture risk: Paget fractures at load-bearing sites such as the femur and tibia often require surgical internal fixation, and compared with ordinary fractures, surgery is more difficult and carries a risk of complications.

Paget sarcoma: Paget sarcoma rarely (<1%) develops in other bones (especially the pelvis and femur) and has a very poor prognosis. Rapid worsening of pain and a sharp rise in ALP are evaluated promptly.

12. Prevention

The same principles as for Paget disease of the skull apply to prevention of Paget disease of other bones. Primary prevention is not possible, but early diagnosis is possible through genetic counseling and family screening.

In SQSTM1 variant carriers, regular monitoring of serum ALP (every 3–5 years) allows early diagnosis before symptoms appear. Preventing complications (nerve compression, fractures, deformity) with early treatment is key. Fall prevention (physical therapy, assistive devices, home environment improvements) reduces the risk of Paget fractures. To prevent osteonecrosis of the jaw during bisphosphonate treatment, patients should consult their physician before dental procedures and maintain thorough oral hygiene. Calcium (1,000–1,200 mg/day) and vitamin D (800–2,000 IU/day) supplementation supports bone health.

13. References

  1. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-4422. DOI: 10.1210/jc.2014-2910. PMID: 25406789.
  2. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372(9633):155-163. DOI: 10.1016/S0140-6736(08)61035-1. PMID: 18620951.
  3. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898-908. PMID: 16135834.
  4. Whyte MP. Paget's disease of bone. N Engl J Med. 2006;355(6):593-600. DOI: 10.1056/NEJMcp060066. PMID: 16899778.
  5. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res. 2010;25(1):20-31. DOI: 10.1359/jbmr.090709. PMID: 19580465.
  6. Falchetti A. Genetics of Paget's disease of bone. Clin Cases Miner Bone Metab. 2006;3(2):103-109. PMID: 22460006.
  7. Donath J, Poor G, Kiss C, Fornet B, Genant H. Atypical Paget disease of bone: review of the histological and radiological features. J Rheumatol. 2004;31(3):628-632. PMID: 14994413.
  8. Michou L, Brown JP. Genetics of bone diseases: Paget's disease. Joint Bone Spine. 2011;78(3):252-258. PMID: 20843731.
  9. Hamdy RC, Moore S, LeRoy J. Clinical presentation of Paget's disease of the bone in older patients. South Med J. 1993;86(10):1097-1100. PMID: 8405537.
  10. Kim HJ, Lee YS, Park YS, et al. Paget's disease of bone in Korea: analysis of Korean patients registered from 2010 to 2020. J Bone Metab. 2022;29(2):95-103. DOI: 10.11005/jbm.2022.29.2.95. PMID: 35726705.